Literature DB >> 92567

Synthesis and antitumor activity of 5-azacytosine arabinoside.

J A Beisler, M M Abbasi, J S Driscoll.   

Abstract

5-Azacytosine arabinoside (ara-AC) can be considered a combination of structural elements derived from the antitumor nucleosides cytosine arabinoside (ara-C) and 5-azacytidine (5-AC). The synthesis of ara-AC, for which standard methods were inadequate, was accomplished using the stable dihydro derivative as a synthetic intermediate. A novel dehydrogenation of the latter through the application of a trimethylsilylation-oxidation procedure gave ara-AC in good yield. Using murine L1210 leukemia as a test system, ara-AC was evaluated for antitumor properties in parallel determinations with 5-AC and ara-C. Although higher dose levels were necessary, ara-AC demonstrated a reproducibly greater efficacy in the L1210 system (% ILS = 144-148) than that shown by 5-AC (% ILS = 126-124) or ara-C (% ILS=127-121 ). Moreover, initial data suggest that ara-AC exhibits less host toxicity than either 5-AC or ARA-C. Although ara-AC can equally be considered an analogue of either 5-AC or ara-C, preliminary results indicate that ara-AC is chemically similar to 5-AC but biologically more closely related to ara-C.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 92567     DOI: 10.1021/jm00196a015

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

Review 1.  Arabinosyl-5-azacytosine: a novel nucleoside entering clinical trials.

Authors:  J L Grem; D D Shoemaker; D F Hoth; S A King; J Plowman; D Zaharko; C K Grieshaber; S D Harrison; J C Cradock; B Leyland-Jones
Journal:  Invest New Drugs       Date:  1987-12       Impact factor: 3.850

2.  Comparison of the activity of arabinosyl-5-azacytosine, arabinosyl cytosine, and 5-azacytidine against intracerebrally implanted L1210 leukemia.

Authors:  J S Driscoll; D G Johns; J Plowman
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

3.  Cerebrospinal fluid pharmacokinetics and toxicology of intraventricular and intrathecal arabinosyl-5-azacytosine (fazarabine, NSC 281272) in the nonhuman primate.

Authors:  R L Heideman; C McCully; F M Balis; D G Poplack
Journal:  Invest New Drugs       Date:  1993 May-Aug       Impact factor: 3.850

4.  Phase I trial of a 72-h continuous-infusion schedule of fazarabine.

Authors:  R Amato; D Ho; S Schmidt; I H Krakoff; M Raber
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Cellular metabolism of 1-beta-D-arabinofuranosyl-5-azacytosine and incorporation into DNA and RNA of human lymphoid CEM/0 and CEM/dCk(-) cells.

Authors:  V I Avramis; W C Powell; R A Mecum
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Arabinofuranosyl-5-azacytosine: activity against human tumors in athymic mice.

Authors:  R E Wallace; D Lindh; F E Durr
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 7.  Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma.

Authors:  Marcelo L Ribeiro; Diana Reyes-Garau; Marc Armengol; Miranda Fernández-Serrano; Gaël Roué
Journal:  Front Genet       Date:  2019-10-16       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.